White R, Rusconi C, Scardino E, Wolberg A, Lawson J, Hoffman M, Sullenger B
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Mol Ther. 2001 Dec;4(6):567-73. doi: 10.1006/mthe.2001.0495.
Species cross-reactivity facilitates the preclinical evaluation of potentially therapeutic molecules in animal models. Here we describe an in vitro selection strategy in which RNA ligands (aptamers) that bind both human and porcine thrombin were selected by "toggling" the protein target between human and porcine thrombin during alternating rounds of selection. The "toggle" selection process yielded a family of aptamers, all of which bound both human and porcine thrombin with high affinity. Toggle-25, a characteristic member, inhibited two of thrombin's most important functions: plasma clot formation and platelet activation. If appropriate targets are available, the toggle strategy is a simple measure that promotes cross-reactivity and may be generalizable to related proteins of the same species as well as to other combinatorial library screening strategies. This strategy should facilitate the isolation of ligands with needed properties for gene therapy and other therapeutic and diagnostic applications.
物种交叉反应性有助于在动物模型中对潜在治疗性分子进行临床前评估。在此,我们描述了一种体外筛选策略,即在交替轮次的筛选过程中,通过在人凝血酶和猪凝血酶之间“切换”蛋白质靶点,来筛选同时结合人和猪凝血酶的RNA配体(适配体)。“切换”筛选过程产生了一系列适配体,它们都以高亲和力结合人和猪凝血酶。典型成员Toggle-25抑制了凝血酶的两个最重要功能:血浆凝块形成和血小板激活。如果有合适的靶点,切换策略是一种促进交叉反应性的简单方法,并且可能适用于同一物种的相关蛋白质以及其他组合文库筛选策略。该策略应有助于分离具有基因治疗及其他治疗和诊断应用所需特性的配体。